Olmesartán Krka (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartán Krka, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Olmesartán Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes. - Heart failure: used as part of combination therapy to improve outcomes in patients with reduced ejection fraction.

Olmesartan medoxil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headed ​​dizziness. - Headache. - Fatigue. - Nasal congestion. - Diarrhoea. - Upper respiratory tract infection.

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue. - Severe hypotension. - Acute kidney injury. - Hyperkalemia. - Liver enzyme elevations. - Bullous skin reactions.

Olmesartan medoxil should be used with caution in several clinical situations.

- Renal impairment: dose may need adjustment and renal function should be monitored. - Hepatic impairment: use with caution; monitor liver enzymes. - Electrolyte disturbances: watch for hyper‑kalaemia, especially with potassium‑sparing diuretics. - Pregnancy     :                             t  t      ...      …  ... ...  ... ...  -        t   t   ewline   ewline  lank \